Postmarketing Reporting of Paxlovid-Related Dysgeusia: A Real-World Pharmacovigilance Study.

David J CvancaraHans C BaertschAshton E LehmannIan M HumphreysNyssa Fox FarrellThomas B MarshallNeel K BhattWaleed M AbuzeidAria Jafari

Published in: Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (2023)

Dysgeusia is much more likely to be reported by patients receiving Paxlovid than those receiving OCT, ritonavir alone, or OPI. These findings suggest a potential mechanism of dysgeusia that causes distorted taste out of proportion to the background effects of COVID-19 infection and specific to nirmatrelvir. Future studies are needed to determine the underlying pathophysiology and long-term clinical implications for patients who report dysgeusia with Paxlovid.

Keyphrases

adverse drug
current status
optical coherence tomography
risk assessment
human health
antiretroviral therapy
case control